期刊
ACS APPLIED MATERIALS & INTERFACES
卷 13, 期 7, 页码 7825-7838出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsami.0c16871
关键词
nanovesicles; RGD targeting; Fabry disease; alpha-galactosidase A (GLA); miristalkonium chloride (MKC)
资金
- European Commission through the H2020 program (Smart-4Fabry project) [720942]
- Instituto de Salud Carlos III (ISCIII)
- European Regional Development Fund (ERDF)
- Ministerio de Ciencia e Innovacion [PID2019-105622RB-I00]
- ISCIII [PI18_00871]
- CIBER-BBN (EXPLORE)
- Protein Production Platform of CIBER-BBN/IBB, at the UAB SepBioES scientific-technical service
- Soft Materials Service linked to Biomaterial Processing and Nanostructuring Unit (U6) at ICMAB-CSIC
- Synthesis of Peptide Unit (U3) at the IQAC-CSIC
- In Vivo Experimental Platform of the Functional Validation & Preclinical Research (FVPR) area
- Generalitat de Catalunya [2017-SGR-1439, 2017-SGR-918]
- FI-AGAUR grant by the Generalitat de Catalunya
- European Social Fund (ESF-Investing in your future) of the European Union
- PERIS grant from the Catalan Government [SLT006/17/270]
- Agencia Estatal de Investigacion-Ministerio de Ciencia e Innovacion through the Severo Ochoa Programme for Centres of Excellence in RD [CEX2019-000917-S]
The incorporation of cationic miristalkonium chloride (MKC) surfactant into RGD nanovesicles has been shown to improve loading capacity and colloidal stability, enhancing the protection and delivery of the enzyme. Using MKC in two different nanosystems increases the stability of enzyme loading, with low concentrations of MKC in hybrid liposomes stabilizing the enzyme without compromising its activity. Hybrid liposomes also show improved efficacy in cell cultures and a good safety profile, ensuring their potential for future preclinical and clinical development.
Fabry disease is a rare lysosomal storage disorder characterized by a deficiency of alpha-galactosidase A (GLA), a lysosomal hydrolase. The enzyme replacement therapy administering naked GLA shows several drawbacks including poor biodistribution, limited efficacy, and relatively high immunogenicity in Fabry patients. An attractive strategy to overcome these problems is the use of nanocarriers for encapsulating the enzyme. Nanoliposomes functionalized with RGD peptide have already emerged as a good platform to protect and deliver GLA to endothelial cells. However, low colloidal stability and limited enzyme entrapment efficiency could hinder the further pharmaceutical development and the clinical translation of these nanoformulations. Herein, the incorporation of the cationic miristalkonium chloride (MKC) surfactant to RGD nanovesicles is explored, comparing two different nanosystems-quatsomes and hybrid liposomes. In both systems, the positive surface charge introduced by MKC promotes electrostatic interactions between the enzyme and the nanovesicles, improving the loading capacity and colloidal stability. The presence of high MKC content in quatsomes practically abolishes GLA enzymatic activity, while low concentrations of the surfactant in hybrid liposomes stabilize the enzyme without compromising its activity. Moreover, hybrid liposomes show improved efficacy in cell cultures and a good in vitro/in vivo safety profile, ensuring their future preclinical and clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据